Structure−Activity Relationships of a Series of Pyrrolo[3,2-d]pyrimidine Derivatives and Related Compounds as Neuropeptide Y5 Receptor Antagonists
Citations Over TimeTop 22% of 2000 papers
Abstract
Neuropeptide Y (NPY) has been shown to play an important role in the regulation of food intake and energy balance. Pharmacological data suggests that the Y5 receptor subtype contributes to the effects of NPY on appetite, and therefore a Y5 antagonist might be a useful therapeutic agent for the treatment of obesity. In attempts to identify potential Y5 antagonists, a series of pyrrolo[3, 2-d]pyrimidine derivatives was prepared and evaluated for their ability to bind to Y5 receptors in vitro. We report here the synthesis and initial structure-activity relationship investigations for this class of compounds. The target compounds were prepared by a variety of synthetic routes designed to modify both the substitution and the heterocyclic core of the pyrrolo[3,2-d]pyrimidine lead 1. In addition to identifying several potent Y5 antagonists for evaluation as potential antiobesity agents, a pharmacophore model for the human Y5 receptor is presented.
Related Papers
- → Effect of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246 on neuropeptide Y release(2000)126 cited
- → Neuropeptide Y (NPY)-containing nerves in mammalian ureter(1990)25 cited
- → Pharmacological characterization of neuropeptide Y-(2–36) binding to neuropeptide Y Y1 and Y2 receptors(1996)11 cited
- → Neuropeptide Y in Sympathetic Co‐Transmission: Recent Advances in the Search for Neuropeptide Y Antagonists(1994)21 cited
- → Neuropeptide W/neuropeptide B receptors in GtoPdb v.2023.1(2023)